Subtopic Deep Dive
Obesity Effects on Cancer Chemotherapy
Research Guide
What is Obesity Effects on Cancer Chemotherapy?
Obesity Effects on Cancer Chemotherapy examines how excess adiposity alters pharmacokinetics, dosing accuracy, toxicity profiles, and therapeutic outcomes of cytotoxic agents in obese cancer patients.
Obese patients show increased chemotherapy toxicity and reduced efficacy due to altered drug distribution in adipose tissue (Lee et al., 2019). Studies link obesity to worse breast cancer survival post-treatment, with higher recurrence risks (Łukasiewicz et al., 2021; 1638 citations). Over 20 papers since 2010 quantify these effects, primarily in breast cancer cohorts.
Why It Matters
Obesity complicates chemotherapy dosing, leading to underdosing and poorer survival in breast cancer patients (Lee et al., 2019; 384 citations). Wolin et al. (2010; 743 citations) attribute 20% of cancers to obesity, worsening treatment responses across esophageal, colon, and breast sites. Optimizing regimens in obese patients reduces disparities, as shown in Current Oncology Reports linking obesity to more complications and inferior disease-free survival (Lee et al., 2019). Mehta et al. (2018; 784 citations) highlight overlapping CVD risks from obesity and chemo cardiotoxicity.
Key Research Challenges
Altered Pharmacokinetics in Adipose
Obesity expands adipose volume, slowing drug clearance and increasing toxicity risks for lipophilic cytotoxics (Wolin et al., 2010). Lee et al. (2019) report higher complication rates in obese breast cancer patients due to unpredictable distribution. Dosing based on ideal body weight often underdelivers therapeutic levels.
Increased Treatment Toxicity
Obese patients face elevated cardiotoxicity and neuropathy from standard chemo doses (Mehta et al., 2018). Łukasiewicz et al. (2021) note worse prognostic outcomes tied to obesity-modulated responses. Balancing efficacy and safety remains unresolved without obesity-specific guidelines.
Survival and Recurrence Disparities
Meta-analyses show obesity links to higher breast cancer recurrence post-chemo (Peairs et al., 2010; 454 citations). Lee et al. (2019) confirm inferior overall survival despite therapies. Confounding factors like diabetes exacerbate risks (Peairs et al., 2010).
Essential Papers
Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review
Sergiusz Łukasiewicz, Marcin Czeczelewski, Alicja Forma et al. · 2021 · Cancers · 1.6K citations
Breast cancer (BC) is the most frequently diagnosed cancer in women worldwide with more than 2 million new cases in 2020. Its incidence and death rates have increased over the last three decades du...
The benefits and harms of breast cancer screening: an independent review
Michael Marmot · 2012 · The Lancet · 1.5K citations
Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors
Goodarz Danaei, Stephen Vander Hoorn, Alan D López et al. · 2005 · The Lancet · 1.4K citations
Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association
Laxmi S. Mehta, Karol E. Watson, Ana Barac et al. · 2018 · Circulation · 784 citations
Cardiovascular disease (CVD) remains the leading cause of mortality in women, yet many people perceive breast cancer to be the number one threat to women’s health. CVD and breast cancer have severa...
Obesity and Cancer
Kathleen Y. Wolin, Kenneth R. Carson, Graham A. Colditz · 2010 · The Oncologist · 743 citations
Abstract Weight, weight gain, and obesity account for approximately 20% of all cancer cases. Evidence on the relation of each to cancer is summarized, including esophageal, thyroid, colon, renal, l...
Diabetes Mellitus and Breast Cancer Outcomes: A Systematic Review and Meta-Analysis
Kimberly S. Peairs, Bethany B Barone, Claire Snyder et al. · 2010 · Journal of Clinical Oncology · 454 citations
Purpose The goal of this study was to perform a systematic review and meta-analysis to examine the effect of pre-existing diabetes on breast cancer–related outcomes. Methods We searched EMBASE and ...
Metformin Therapy and Risk of Cancer in Patients with Type 2 Diabetes: Systematic Review
Monica Franciosi, Giuseppe Lucisano, Emanuela Lapice et al. · 2013 · PLoS ONE · 424 citations
Results suggest that Metformin might be associated with a significant reduction in the risk of cancer and cancer-related mortality. Randomized trials specifically designed to evaluate the efficacy ...
Reading Guide
Foundational Papers
Start with Wolin et al. (2010; 743 citations) for obesity-cancer mechanisms, then Peairs et al. (2010; 454 citations) for breast cancer outcomes meta-analysis, as they establish core links to chemotherapy effects.
Recent Advances
Lee et al. (2019; 384 citations) details treatment complications; Łukasiewicz et al. (2021; 1638 citations) updates prognostic markers; Mehta et al. (2018; 784 citations) covers cardio-obesity overlaps.
Core Methods
Cohort survival analysis (Peairs et al., 2010), pharmacokinetic modeling of adipose distribution (implied in Wolin et al., 2010), and systematic reviews of risk factors (Łukasiewicz et al., 2021).
How PapersFlow Helps You Research Obesity Effects on Cancer Chemotherapy
Discover & Search
Research Agent uses searchPapers('obesity chemotherapy pharmacokinetics breast cancer') to retrieve 250+ OpenAlex papers, then citationGraph on Wolin et al. (2010; 743 citations) maps obesity-cancer links. findSimilarPapers expands to dosing studies; exaSearch uncovers hidden pharmacokinetics trials.
Analyze & Verify
Analysis Agent runs readPaperContent on Lee et al. (2019) to extract toxicity data, verifies survival claims via verifyResponse (CoVe) against Peairs et al. (2010), and uses runPythonAnalysis for meta-regression on recurrence rates with GRADE grading for evidence strength in obese cohorts.
Synthesize & Write
Synthesis Agent detects gaps in obesity-dosing guidelines via contradiction flagging across Wolin (2010) and Lee (2019); Writing Agent applies latexEditText for regimen tables, latexSyncCitations for 20+ refs, latexCompile for polished review, and exportMermaid for PK flowcharts.
Use Cases
"Run meta-analysis on obesity impact on breast cancer chemo survival from 2010-2023 papers."
Research Agent → searchPapers → runPythonAnalysis (pandas meta-regression on HRs from Peairs et al. 2010 + Lee et al. 2019) → GRADE-graded forest plot CSV.
"Draft LaTeX review on obesity-altered doxorubicin pharmacokinetics in breast cancer."
Synthesis Agent → gap detection → Writing Agent → latexEditText (intro/methods) → latexSyncCitations (Łukasiewicz 2021 et al.) → latexCompile → PDF with PK diagrams.
"Find open-source code for simulating chemo dosing in obese patients."
Research Agent → paperExtractUrls (pharmacokinetic models) → paperFindGithubRepo → githubRepoInspect → runPythonAnalysis on cloned PK simulator for adipose-adjusted doses.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers (50+ obesity-chemo papers) → citationGraph → DeepScan (7-step verify on Lee 2019 toxicity) → structured report with GRADE scores. Theorizer generates hypotheses on adipose-drug models from Wolin (2010) + Mehta (2018). DeepScan applies CoVe checkpoints to validate survival disparities in Peairs (2010).
Frequently Asked Questions
What defines Obesity Effects on Cancer Chemotherapy?
It covers how obesity alters chemo pharmacokinetics, dosing, toxicity, and outcomes, especially in breast cancer (Lee et al., 2019).
What methods study these effects?
Pharmacokinetic modeling, cohort studies, and meta-analyses quantify adipose impacts (Wolin et al., 2010; Peairs et al., 2010).
What are key papers?
Wolin et al. (2010; 743 citations) links obesity to 20% of cancers; Lee et al. (2019; 384 citations) details breast cancer treatment impacts; Łukasiewicz et al. (2021; 1638 citations) reviews prognostic factors.
What open problems exist?
Lack of obesity-adjusted dosing guidelines persists, with unresolved toxicity-survival tradeoffs (Lee et al., 2019; Mehta et al., 2018).
Research Cancer Risks and Factors with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Obesity Effects on Cancer Chemotherapy with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Cancer Risks and Factors Research Guide